AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies how well AXL inhibitor BGB324 works in treating participants with
glioblastoma that has come back who are undergoing surgery. AXL inhibitor BGB324 may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth.
Phase:
Early Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins